Solid tumor
Conditions
Interventions
immunotherapy:Immune checkpoint inhibitors
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years old, male or female; 2. The patients are diagnosed as solid tumor via histologic and cytology; 3. Clinical stage is stage IIIB-IV; 4. Have one measurable lesions at least according to RECIST 1.1 standard; 5. ECOG PS 0-1; 6. The expected lifetime of patients should be more than 3 months; 7. No previous ICB antitumor therapy; 8. Biochemical examination should meet the following criteria: (1) TBIL = 40mL/min; 9. The main viscera function of patients should meet the following requirements: (1) Hb >= 9.0 g/dL; (2) ANC >= 1.5 x 10^9/L; (3) PLT >= 100 x 10^9/L; 10. The patients are willing to join in this study, and have signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Tumors of the hematologic system; 2. A history of severe allergies, allergies or other allergic reactions to chimeric or humanized antibodies or fusion proteins; 3. Severe autoimmune disease; 4. Immunosuppressive drugs were administered 2 weeks prior to enrollment; 5. Oral dosage of more than 10mg of prednisone or isodose hormone per day; 6. Severe infections requiring antimicrobial treatment 2 weeks prior to enrollment; 7. Severe pulmonary dysfunction before enrollment; 8. Severe comorbidity precludes the possibility of treatment; 9. Other conditions considered inappropriate by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Safety;Progression Free Survival;disease control rate;Duration of Response; | — |
Countries
China
Contacts
Public ContactShen Bo
Jiangsu Cancer Hospital
Outcome results
None listed